China As China’s biotech industry races into next-generation modalities, Epigenic Therapeutics is seeking to open a new frontier by regulating gene expression without cutting DNA. In conversation with Bob Zhang, the company’s CEO and co-founder, he explains how science originating from the Chinese Academy of Sciences is being translated into a…
USA Priya Kishnani, Director of the Division of Medical Genetics at Duke University School of Medicine, discusses how multidisciplinary care, global collaboration, and rapidly advancing therapeutic technologies are reshaping the rare disease landscape. Drawing on decades of experience across diagnosis, natural history research, and the development of transformative treatments, she outlines…
USA Dr Jerry Vockley, Director of the Center for Rare Disease Therapy and Chief of the Division of Medical Genetics at UPMC Children’s Hospital of Pittsburgh, offers a look at the evolving landscape of rare disease care across early diagnosis, newborn screening, natural history research, clinical trial design, and the persistent…
Switzerland Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation. For instance, in Bellinzona, the capital of the Italian-speaking Ticino canton, the Institute of Oncology Research (IOR) is working with…
Switzerland In the age of AI-fuelled promises and digital transformation, SOPHiA GENETICS stands apart, not by chasing trends but by quietly reshaping how healthcare systems use data to deliver more precise, equitable, and timely care. From enabling cloud-native genomics in hospitals worldwide to advancing decentralised liquid biopsy, the company is building…
Switzerland At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges with the findings published in the Swiss Biotech Report 2023. The organisation also celebrated recent industry successes with its Swiss…
USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…
Hong Kong A groundbreaking research scientist noted for his work in non-invasive blood-based diagnoses, Professor Dennis Lo currently holds a number of positions at the Chinese University of Hong Kong (CUHK). Lo, whose work was first commercialised via the company Cirina – later acquired by GRAIL – outlines his current research focus on…
Sweden Svante Paabo has won the 2022 Nobel Prize in physiology or medicine for his ground-breaking work in paleogenetics. Paabo’s research – which includes sequencing the genome of the Neanderthal for the first time – has wide-ranging implications for the study of human evolution, as well as in the development of…
Saudi Arabia Few stakeholders are better placed to assess the landscape for rare disease therapies across the Middle East and North Africa (MENA) region than Karim Smaira and Kamel Ghammachi of Genpharm, an entrepreneurial success story that now provides market access and marketing solutions for rare disease products across the region. …
UAE As part of its endeavour to provide world-class healthcare, on December 10 2019, the Abu Dhabi Department of Health (DoH) announced a national program to use large-scale genomic data with the aim of allowing doctors working in the Emirate to provide more personalized and preventive treatment. The Genome Program…
UAE With a relatively high number of genetic disorders, the Arab population of the United Arab Emirates (UAE) is increasingly becoming the subject of new studies. The database from the Center for Arab Genomics Studies indicates the presence of 241 genetic disorders among that demographic, a number they call “extremely high…
See our Cookie Privacy Policy Here
